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Objective: Hsa-miR-148a expression is decreased in Osteoarthritis (OA) cartilage, but its functional role in
cartilage has never been studied. Therefore, our aim was to investigate the effects of overexpressing hsa-
miR-148a on cartilage metabolism of OA chondrocytes.
Design: OA chondrocytes were transfected with a miRNA precursor for hsa-miR-148a or a miRNA pre-
cursor negative control. After 3, 7, 14 and 21 days, real-time PCR was performed to examine gene
expression levels of aggrecan (ACAN), type I, II, and X collagen (COL1A1, COL2A1, COl10A1), matrix
metallopeptidase 13 (MMP13), a disintegrin and metalloproteinase with thrombospondin motifs 5
(ADAMTS5) and the serpin peptidase inhibitor, clade H (heat shock protein 47), member 1 (SERPINH1).
After 3 weeks, DNA content and proteoglycan and collagen content and release were determined. Type II
collagen was analyzed at the protein level by Western blot.
Results: Overexpression of hsa-miR-148a had no effect on ACAN, COL1A1 and SERPINH1 gene expression,
but increased COL2A1 and decreased COL10A1, MMP13 and ADAMTS5 gene expression. Luciferase re-
porter assay conﬁrmed direct interaction of miR-148a and COL10A1, MMP13 and ADAMTS5. The matrix
deposited by the miR-148a overexpressing cells contained more proteoglycans and collagen, in particular
type II collagen. Proteoglycan and collagen release into the culture medium was inhibited, but total
collagen production was increased.
Conclusion: Overexpression of hsa-miR-148a inhibits hypertrophic differentiation and increases the
production and deposition of type II collagen by OA chondrocytes, which is accompanied by an increased
retention of proteoglycans. Hsa-miR-148a might be a potential disease-modifying compound in OA, as it
promotes hyaline cartilage production.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a major cause of physical disability due to
symptoms as pain, stiffness and loss of mobility. Multiple factors
are believed to cause OA, such as trauma, abnormal mechanical
loading, failure of nutrient supply and genetic predisposition1.
Available treatments are limited to pain management and in end-
stage OA patients, joint replacement surgery is often indicated.
OA is characterized by local inﬂammation, synovitis and proteolytic
degradation of cartilage, which correlates with alterations in
chondrocyte expression levels of genes involved in synthesis and
degradation of cartilage1e4.: L.A. Vonk, Department of
Box 85090, 3584 CX Utrecht,
).
s Research Society International. PRecently, it was proposed that epigeneticmechanisms play a role
in modulating cell phenotype in OA5e10, resulting in permanent
changes in DNA transcription. One of the epigenetic mechanisms
involved is based on microRNA (miRNA) expression6,8. MiRNAs are
short (19e24 nucleotide long) non-coding RNA molecules that can
silence gene expression by binding to complementary sequences on
targetmessenger RNA (mRNA) transcripts, resulting in translational
repression or target degradation. Approximately one-third of all
mammalian genes are regulated by miRNAs11.
Changes in miRNA expression patterns are found in many
pathological conditions, including several malignancies and
neurological, cardiovascular and developmental diseases12e16. The
role of miRNAs in joint homeostasis has become evident from
studies showing major abnormalities in cartilage development and
structure in Dicer-null mice17. The miRNA expression pattern is also
changed in OA and several miRNAs, including hsa-miR-27, 140, 145,
146a and 675 were found to be associated with altered levels ofublished by Elsevier Ltd. All rights reserved.
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involvements of the abovementionedmiRNAs in OAwere analyzed,
the effects of modulating these miRNAs on cartilage regeneration,
in particular at the protein level, is unknown.
Typically, studies on the possible involvement of miRNAs in
pathological processes start with miRNA screens to identify po-
tential candidates. Previously, screens of 365 and 115 miRNAs,
respectively, were proﬁled in normal and OA cartilage18,19. In the
scope of performing a more extensive miRNA screen, we found that
hsa-miR-148a was expressed at 10.6 times lower levels in OA
cartilage compared to normal cartilage (unpublished observations),
in line with previously published results19. However, the functional
role of hsa-miR-148a in cartilage metabolism or speciﬁcally OA has
never been studied. Hsa-miR-148a has some predicted targets that
are relevant for OA and general chondrocyte biology. Amongst the
predicted targets are the mRNAs for type II collagen (COL2A1), type
X collagen (COL10A1), matrix metallopeptidase 13 (MMP13), a
disintegrin and metalloproteinase with thrombospondin motifs 5
(ADAMTS5) and the collagen chaperone serpin peptidase inhibitor,
clade H (heat shock protein 47), member 1 (SERPINH1)30. There-
fore, the aim of this study was to investigate the effects of over-
expressing hsa-miR-148a on cartilage metabolism of OA
chondrocytes during regeneration.
Materials and methods
MiRNA expression screen
Total RNAwas isolated from articular cartilagewith themirVana
miRNA isolation kit (Ambion, Austin, TX) according to the manu-
facturer’s protocol. Healthy human cartilage from femoral condyles
of knee joints was obtained post-mortem of three male donors and
four female donors, the mean agewas 65 years (range: 47 yearse83
years). OA cartilage was obtained from three male and four female
donors (age 53e80, average 69 years) undergoing total knee
arthroplasty. cDNA was synthesized using TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystems, Life technologies,
Poland) with Megaplex RT Primers, Human Pool A and B v3.0 ac-
cording to the manufacturer’s protocol. The TaqMan low-density
Arrays A and B (TaqMan Array Human MicroRNA A v3.0 and B
v3.0 Card Sets, Applied Biosystems) were used in a ABI Prism
7900HT sequence detection system (Applied Biosystems). The raw
Ct values were calculated using RQmanager software and analyzed
using DataAssist software (ABI, Applied Biosystems).
Cell isolation
Chondrocytes were isolated from articular cartilage from pa-
tients with OA undergoing total knee arthroplasty. The anonymous
use of redundant tissue for research purposes is part of the stan-
dard treatment agreement with patients in the University Medical
Center Utrecht31. The articular cartilagewasminced and digested in
0.15% (w/v) collagenase (CLS-2, Worthington, Lakewood, NJ) in
Dulbecco’s modiﬁed Eagle’s medium (DMEM, Gibco, Paisley, UK)
supplemented with 10% fetal bovine serum (FBS, HyClone, Logan,
UT), 100 U/ml penicillin (Gibco) and 100 mg/ml streptomycin
(Gibco) for 16 h at 37C.
The cells were ﬁltered through a 100 mm cell strainer (BD Bio-
sciences, San Diego, CA) and washed before culturing or miRNA/
mRNA isolation.
Cell culture and transfection
Isolated OA chondrocytes were expanded in T175 tissue culture
ﬂasks in DMEM supplemented with 10% FBS, 100 U/ml penicillin,100 mg/ml streptomycin, and 10 ng/ml bFGF (R&D, Minneapolis,
MN), at 37C in 5% CO2. At conﬂuency, the cells were trypsinized
using 0.25% trypsin/EDTA (Gibco) and replated.
At passage 2, OA chondrocytes were reverse-transfected with a
pre-mir miRNA precursor for hsa-miR-148a-5p or a pre-mir miRNA
precursor negative control (Ambion) using Lipofectamine RNAiMax
(Invitrogen, Carlsbad, CA). The reverse-transfection was performed
during seeding (density 1.6  106 cells/cm2) on Millicell ﬁlters
(0.4 mm PFTE (Millipore, Bedford, MA)) that were precoated with
type II collagen (type II collagen from chicken sternal cartilage
(Sigma, St. Louis, MO))32,33. The ﬁnal concentration of pre-mir
miRNA precursor was 10 nM. The cells were retransfected after 1
and 2 weeks of culture on ﬁlters.
The ﬁlters were cultured in DMEM (Gibco) supplemented with
10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin and 50 mg/ml
ascorbate-2-phosphate (Sigma) and culture media were renewed
every 3 days.
MiRNA real-time PCR
Total RNA was extracted from chondrocytes with the mirVana
miRNA isolation kit (Ambion) according to the manufacturer’s
protocol. The expression of hsa-miR-148a was veriﬁed using a
TaqMan miRNA assay for hsa-miR-148a (Applied Biosystems).
MiRNA expression was normalized to RNU44 small nuclear RNA.
Real-time PCR
Total RNA was isolated from the cells immersed in Trizol (Invi-
trogen) as described by the manufacturer. Total RNA (750 ng) was
reverse transcribed using an iScript cDNA Synthesis Kit (Biorad,
Hercules, CA).
Real-time PCR reactions were performed using the SYBR Green
reaction kit according to the manufacturer’s instructions (Roche
Diagnostics, Mannheim, Germany) in a LightCycler 480 (Roche
Diagnostics). The LightCycler reactions were prepared in 20 ml total
volume with 7 ml PCR-H2O, 0.5 ml forward primer (0.2 mM), 0.5 ml
reverse primer (0.2 mM), 10 ml LightCycler Mastermix (LightCycler
480 SYBR Green I Master; Roche Diagnostics), to which 2 ml of ﬁve
times diluted cDNA was added as PCR template. Primers (Invi-
trogen) used for real-time PCR are listed in Table I. Speciﬁc primers
were designed from sequences available in the data banks, based
on homology in conserved domains between human, mouse, rat,
dog and cow34. The ampliﬁed PCR fragment extended over at least
one exon border (except for 18S). Tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, zeta polypeptide
(YWHAZ) and 18S were used as housekeeping genes and the gene
expression levels were normalized for the normalization factor
calculated with the equation O(YWHAZ  18S). With the Light
Cycler software (version 4), the crossing points were assessed and
plotted vs the serial dilution of known concentrations of the stan-
dards derived from each gene using Fit Points method. PCR efﬁ-
ciency was calculated by Light Cycler software and the data were
used only if the calculated PCR efﬁciency was between 1.85 and 2.0.
Papain digestion
After 3 weeks of culture, ﬁlters were digested at 60C for 18 h in
a papain enzyme solution consisting of 5 mM L-cysteine, 50 mM
Na2EDTA, 0.1 M NaAc, pH 5.53 with 2% (v/v) papain (Sigma).
Proteoglycan analysis
To analyze the proteoglycan content of the regenerated cartilage
tissue and the amount released into the culture medium, a
Table II
Oligonucleotide sequences used for amplifying 30 UTRs
30 UTR of
target gene
Oligonucleotide sequence
COL2A1
sense
Fw CCGCTCGAGAAACCTGAACCCAGAAAC
Rev CGTACGCCGGCGGTACTTTCCAATAATCTTTTC
COL2A1
antisense
FW GCATGCGGCCGCAAACCTGAACCCAGAAACAAC
Rev CGTACTCGAGGTACTTTCCAATAATCTTTTC
COL10A1
sense
Fw CCGCTCGAGGTACACACAGAGCTAATCTAAATC
Rev CGTACGCCGGCGCACTTTATTGTCCTACTTTTTTATTAAC
COL10A1
antisense
Fw GCATGCGGCCGCGTACACACAGAGCTAATCTAAATC
Rev CGTACTCGAGCACTTTATTGTCCTACTTTTTTATTAAC
MMP13
sense
Fw CCGCTCGAGGTGTCTTTTTAAAAATTGTTATT
Rev CGTACGCCGGCGCTGTTGAAAATATATTTTTATTATAAAC
MMP13
antisense
Fw GCATGCGGCCGCGTGTCTTTTTAAAAATTGTTATT
Rev CGTACTCGAGCTGTTGAAAATATATTTTTATTATAAAC
ADAMTS5
sense
Fw CCGCTCGAGCCTGTGGTTATGATCTTATGCAC
Rev CGTACGCCGGCGACTTTAACCTAGTTTACAATTTATAT
ADAMTS5
antisense
Fw GCATGCGGCCGCCCTGTGGTTATGATCTTATGCAC
Rev CGTACTCGAGACTTTAACCTAGTTTACAATTTATAT
SERPINH1
sense
Fw CCGCTCGAGGGCCTCAGGGTGCACACAGGATG
Rev CGTACGCCGGCGCCACGCTCCAACAAAATGTCATTGG
SERPINH1
antisense
Fw GCATGCGGCCGCGGCCTCAGGGTGCACACAGGATG
Rev CGTACTCGAGCCACGCTCCAACAAAATGTCATTGG
Forward (Fw) and reverse (Rev) primers for COL2A1, a1(II)procollagen; COL10A1,
a1(X)procollagen; MMP13; ADAMTS5; SERPINH1.
Table I
Oligonucleotide sequences used for real-time PCR
Target
gene
Oligonucleotide sequence Annealing
temperature
(C)
Product
size (bp)
18S Fw 50 GTAACCCGTTGAACCCCATT 30 57 151
Rev 50 CCATCCAATCGGTAGTAGCG 30
YWHAZ Fw 50 GATGAAGCCATTGCTGAACTTG 30 56 229
Rev 50 CTATTTGTGGGACAGCATGGA 30
ACAN Fw 50 CAACTACCCGGCCATCC 30 57 160
Rev 50 GATGGCTCTGTAATGGAACAC 30
COL1A1 Fw 50 TCCAACGAGATCGAGATCC 30 57 191
Rev 50 AAGCCGAATTCCTGGTCT 30
COL2A1 Fw 50 AGGGCCAGGATGTCCGGCA 30 56 195
Rev 50 GGGTCCCAGGTTCTCCATCT 30
COL10A1 Fw 50 CACTACCCAACACCAAGACA 30 56 225
Rev 50 CTGGTTTCCCTACAGCTGAT 30
MMP13 Fw 50 GGAGCATGGCGACTTCTAC 30 56 208
Rev 50 GAGTGCTCCAGGGTCCTT 30
ADAMTS5 Fw 50 GCCAGCGGATGTGTGCAAGC 30 57 130
Rev 50 ACACTTCCCCCGGACGCAGA 30
SERPINH1 Fw 50 TGATGATGCACCGGACAG 30 57 212
Rev 50 GGAGATGGCAACAGCCTTC 30
Forward (Fw) and reverse (Rev) primers for YWHAZ; ACAN; COL1A1, a1(I)pro-
collagen; COL2A1, a1(II)procollagen; COL10A1, a1(X)procollagen; MMP13;
ADAMTS5; SERPINH1.
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performed to determine the content of sulfated glycosaminogly-
cans (GAGs)35. DMMB solution and papain digest or medium
sample were mixed and the absorbance was read at 540 nm and
595 nm. As reference, chondroitin sulfate C (Sigma) was used. The
total amount of proteoglycans produced was deﬁned as the amount
of proteoglycans in the papain tissue digest and the amount of
proteoglycans released into the culture medium during the entire
culture period.
DNA content
Total DNA was quantiﬁed in papain digests using Quant-iT
Picogreen (Invitrogen) according to the manufacturer’s in-
structions. Picogreen reagent was added to papain digest. This was
incubated at ambient temperature for 5 min, protected from light.
The ﬂuorescence was measured at w480 nm excitation and
w520 nm emission and DNA content determined using lambda
DNA as standard.
Hydroxyproline assay
To analyze the collagen content, hydroxyproline content was
determined in papain digests or medium samples using a modiﬁed
colorimetric assay36. In short, freeze-dried papain digests or me-
dium samples were hydrolyzed and the free hydroxyprolines were
oxidized with Chloramine-T for the production of pyrroles. The
addition of Ehrlich’s reagent resulted in the formation of chromo-
phores that were measured at 550 nm and collagen content was
determined using gelatin (Sigma) as standard. The total amount of
collagens produced was deﬁned as the amount of collagens found
in the papain digest and the amount of collagens released into the
culture medium.
Type II collagen Western blot
After 3 weeks of culture, ﬁlters were digested overnight at 4C
with pepsin (Worthington, 100 mg/ml in 0.2 M NaCl, 0.5 M acetic
acid). The digests and 0.05, 0.025, and 0.005 mg of type II collagen asreference (chicken sternum, Sigma) were denatured by heating at
95C for 5 min in NuPage LDS sample buffer (Invitrogen) with
NuPage reducing agent (Invitrogen). The digests and collagen
standards were resolved by SDS-PAGE (8% resolving gel with 4%
stacking gel) and transferred to nitrocellulose membranes (Biorad).
The membranes were blocked in 2% (w/v) BSA 0.1% Tween in
phosphate buffered saline (PBS) for 1 h and were then incubated
with the primary antibody for 2 h. Mouse monoclonal anti-type II
collagen (MAB1330, Chemicon, Millipore) was used at 1:1000
dilution. After threewasheswith 0.1% Tween in PBS, themembranes
were incubated with horseradish peroxidase-conjugated anti-
mouse secondary antibody (DakoCytomation, Glostrup, Denmark)
at a 1:5000 dilution for 1 h. Following three washes, immunoreac-
tivity was visualized using Lumi-Lightplus (Roche Diagnostics).Luciferase assay
The 30 untranslated regions (30 UTRs) of type II and type X
collagen (COL2A1 and COL10A1), MMP13, ADAMTS5 and
SERPINH1 were ampliﬁed by PCR with DNA oligonucleotides
ﬂanked by XhoI and NotI restriction sites (DNA oligonucleotide
sequences are listed in Table II). The fragments were cloned
downstream of the Renilla luciferase gene into the pSICHECK2
vector (Promega, Madison, WI) in sense and antisense orientation.
Hela cells were plated into 96-wells plates and cotransfected
with the described luciferase reporter constructs and 50nMpre-mir
miRNA precursor for hsa-miR-148a or a pre-mir miRNA precursor
negative control (Ambion) using Lipofectamine (Invitrogen). Lumi-
nescencewasmeasured 48 h after transfection using Pierce Renilla-
Fireﬂy Luciferase Dual Assay Kit (Thermo scientiﬁc, Rockford, IL).Collagenase activity assay
To analyze collagenase activity, the Enzchek Gelatinase/Colla-
genase Assay Kit (Invitrogen) was used according to the manufac-
turer’s instructions. DQ Collagen Fluorescein conjugate was added
to 100 times in reaction buffer (kit component) diluted conditioned
medium. This was incubated for 4 h at ambient temperature, pro-
tected from light. The ﬂuorescence was measured at w480 nm
Fig. 1. Real-time PCR was performed for hsa-miR-148a, type II collagen (COL2A1), type X collagen (COL10A1), MMP13, ADAMTS5 and SERPINH1 on reverse transcribed RNA isolated
from osteoarthritic cartilage (seven donors) and normal cartilage (seven donors). The data are presented in a dot plot where every dot resembles the value of one donor. The mean
value of the samples is indicated by a line. Data are shown as mean  SD. ***: P < 0.001.
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determined using collagenase type IV from Clostridium histo-
lyticum (kit component) as standard.
Statistical analysis
Gene expression data are expressed as mean  SD of miR-148a
transfected vs mock transfected chondrocytes of target gene
expression normalized for the equation O(YWHAZ  18S). Differ-
ences in expression ratios were tested with a two-tailed t-test for
single group mean and compared to 1 (miR-148a transfected/mock
transfected ¼ 1, no effect). Data from biochemical assays are
expressed in dot plots where every dot resembles the value of one
donor and the mean value of the samples is indicated by a line. The
data were analyzed using a two-tailed paired t-test. The level of
signiﬁcance was set at P< 0.05. Normal distribution of the datawas
conﬁrmed using the ShapiroeWilk test.
Results
Hsa-miR-148a regulates COL10A1, MMP13 and ADAMTS5
In the scope of performing an extensive miRNA screen between
normal and OA cartilage, we had found that hsa-miR-148a was
expressed about ten times less in OA cartilage compared to normal
cartilage. By real-time PCR it was conﬁrmed that hsa-miR-148a
levels were nine fold lower in OA cartilage compared to normal
cartilage [Fig. 1(A)].
TargetScan 6.2 and/or microRNA.org identiﬁed COL2A1,
COL10A1, MMP13, ADAMRS5 and SERPINH1 amongst the predictedtargets of hsa-miR-148a. The gene expression levels of these genes
were measured in the same RNA in which hsa-miR-148a levels
were determined. The expression level of COL2A1 was decreased in
the OA donors [Fig. 1(B)], the levels of COL10A1, MMP13 and
ADAMTS5 were increased in OA donors [Fig. 1(C)e(E)], and for
SERPINH1 no difference was observed [Fig. 1(F)].
To investigate the effects of upregulation of hsa-miR-148a, a
miRNA precursor (pre-mir) for hsa-miR-148a or a pre-mir negative
control was transfected in OA chondrocytes. Real-Time PCR analysis
conﬁrmed that transfection of the pre-mir increased the expression
of hsa-miR-148a compared to transfectionwith control non-coding
pre-miRNA [Fig. 2]. The upregulation of hsa-miR-148a expression
was highest 3 days after the initial transfection, with a 5-fold in-
crease compared to the precursor negative control. Just before the
re-transfections at days 7 and 14 and at the end of the culture
period of 3 weeks, the hsa-miR-148a expression levels were up-
regulated about 3.5-fold.
Overexpression of hsa-miR-148a resulted in increased COL2A1,
decreased COL10A1. MMP13 and ADAMTS5, and unchanged SER-
PINH1 gene expression levels [Fig. 2].
To analyze the miRNAemRNA interactions of the predicted
target genes, a luciferase reporter assay was performed. No differ-
ence in luciferase activity was observed between HeLa cells
cotransfected with the construct containing the 30 UTR of COL2A1
and SERPINH1 and the miRNA precursor for hsa-miR-148a or a
miRNA precursor negative control [Fig. 3]. A decrease in luciferase
activity was measured in Hela cells cotransfected with the miRNA
precursor for hsa-miR-148a and the luciferase reporter vector
containing the 30 UTRs of COL10A1, MMP13 and ADAMTS5 in sense
orientation [Fig. 3]. No difference was shown when the 30 UTRs of
Fig. 2. Real-time PCR was performed on reverse transcribed RNA isolated from OA chondrocytes transfected with a pre-mir miRNA precursor for hsa-miR-148a or a pre-mir miRNA
precursor negative control after 3, 7, 14 and 21 days in a regeneration culture. Expression levels of hsa-miR-148a (148a), ACAN, type I collagen (COL1A1), type II collagen (COL2A1),
type X collagen (COL10A1), MMP13, ADAMTS5 and SERPINH1 were measured. The results are presented as expression levels of hsa-miR-148a transfected OA chondrocytes relative
to negative control transfected OA chondrocytes. Data are shown as mean  SD. **: P < 0.01; ***: P < 0.001.
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reporter vector in antisense orientation [Fig. 3].
Overexpression of hsa-miR-148a increases proteoglycan content and
decreases proteoglycan release
Overexpression of hsa-miR-148a had no effect on ACAN gene
expression levels, but did decrease the gene expression levels of the
aggrecanase ADAMTS5 [Fig. 2]. The amount of proteoglycans was
increased in the tissue generated by hsa-miR-148a overexpressing
OA chondrocytes compared to controls [Fig. 4(A)], while proteo-
glycan release into the culture medium was decreased [Fig. 4(B)].
No difference was found between chondrocytes over-
expressing hsa-miR-148a and controls in terms of the totalFig. 3. HeLa cells were cotransfected with 50 nM pre-mir miRNA precursor for hsa-miR-148a
UTRs of type II collagen (COL2A1), type X collagen (COL10A1), MMP13, ADAMTS5 and SERP
48 h after transfection. Data are shown as mean  SD. *: P < 0.05; **: P < 0.01.amount of proteoglycans produced, as determined by adding up
the amount found in the deposited matrix at the end of culture
period and the total amount released into the medium during
culture [Fig. 4(C)].
Overexpression of hsa-miR-148a increases collagen II expression at
the mRNA and protein level and decreases the expression of type X
collagen and MMP13
However, overexpression of hsa-miR-148a resulted in increased
COL2A1 gene expression levels and the gene expression levels of
COL10A1 and the collagenase MMP13 were decreased [Fig. 2]. No
effect was shown on gene expression levels of COL1A1 and the
collagen chaperone SERPINH1 [Fig. 2].or pre-mir miRNA precursor negative control (mock) and pSICHECK2 containing the 30
INH1 in sense and antisense orientation. Fireﬂy and Renilla luciferase were measured
Fig. 4. Proteoglycan content (A), release (B), and total production (C) (determined as GAGs) (normalized for the DNA content) were determined after 21 days in cultures of OA
chondrocytes transfected with a pre-mir miRNA precursor negative control (mock) or a pre-mir miRNA precursor for hsa-miR-148a (miR-148a). The data are presented in a dot plot
where every dot resembles the value of one donor. The mean value of the samples is indicated by a line. *: P < 0.05; ***: P < 0.001.
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by hsa-miR-148a overexpressing OA chondrocytes compared to
controls [Fig. 5(A)], while the amount of collagen released into the
culture medium was decreased [Fig. 5(B)].
In contrast to the lack of effect on total proteoglycan production,
the total amount of collagen produced was increased by hsa-miR-
148a overexpressing OA chondrocytes compared to controls
[Fig. 5(C)].
Collagenase activity was decreased in the culture medium of the
hsa-miR-148a overexpressing OA chondrocytes [Fig. 5(D)].
To verify whether type II collagen was also speciﬁcally up-
regulated at the protein level, an immunoblot for type II collagen
was performed on the collagen extracted from the cultures, con-
ﬁrming the higher deposition of type II collagen by the hsa-miR-
148a overexpressing OA chondrocytes compared to the mock-
transfected OA chondrocytes [Fig. 5(E)].
Discussion
In this study hsa-miR-148a, expressed at lower levels in OA
cartilage compared to healthy cartilage, is suggested to play an
important role in cartilage regeneration. Overexpressing hsa-miR-
148a in OA chondrocytes increases extracellular matrix deposi-
tion by these cells; not only proteoglycan, but also the collagen and
speciﬁcally type II collagen content was increased. In addition,
matrix degradationwas reduced, as reﬂected by a decreased release
of proteoglycans during culture, which was accompanied by
downregulation of MMP13, COL10A1 and ADAMTS5, predicted and
conﬁrmed targets of miR-148a.
Surprisingly, COL2A1, another postulated target gene was found
to be increased upon overexpression of hsa-miR-148a in OA
chondrocytes. This suggests that COL2A1 is not a direct target of
hsa-miR-148a, as miRNAs are by default negative regulators of gene
expression. A luciferase reporter assay also showed no interaction
between miR-148a and COL2A1. However, hsa-miR-148a might
target a repressor of COL2A1 as was also suggested for miR-67528.
The gene expression patterns for collagen and ACAN were also
reﬂected at the protein level. The gene expression level of ACAN,
themain proteoglycan in the cartilaginous extracellular matrix, was
unchanged. Although an increased proteoglycan content was found
after culturing, total proteoglycan production did not increase. Thedecreased proteoglycan release in combination with the decreased
ADAMTS5 expression suggests that the increase in proteoglycan
content was caused by a diminished breakdown, resulting in
increased retention, rather than an increase in synthetic activity.
The increased total collagen and speciﬁcally type II collagen
production found upon overexpression ofmiR-148awas in linewith
the increased gene expression levels of COL2A1. Next to a general-
ized increase in synthetic activity, a higher portion of collagen was
found in the deposited matrix compared to collagen released into
the culturemedium. This coincidedwith decreased gene expression
of MMP13, the main enzyme involved in cartilage collagen degra-
dation. This is supportedby thedecreased collagenase activity found
in the culture medium of the hsa-miR-148a overexpressed chon-
drocytes. So, collagen production was not only increased but its
degradationwas also inhibited.Most likely this increaseddeposition
of collagenwas responsible for the increase in proteoglycan content
found, as an intact collagen network is required for the retention of
proteoglycans inside the cartilage matrix37.
In addition to the stimulatory effects on cartilage matrix for-
mation, the downregulation of COL10A1 gene expression levels by
miR-148a overexpression suggests further reversal of the OA
chondrocytic phenotype, as hypertrophic differentiation charac-
terized by increased COL10A1 expression levels is a hallmark of OA.
In addition to COL2A1 another predicted miR-148a target that
was not affected in line with the sequence-based prediction was
SERPINH1, a collagen-speciﬁc chaperone. This protein is required for
proper intracellular protein folding of the collagens and decreased
SERPINH1 levels might lead to improper collagen folding resulting
in intracellular accumulation and degradation of collagens. How-
ever, miR-148a after all did not seem to target SERPINH1 and
increased production and deposition of collagens by miR-148a
overexpressed OA chondrocytes suggests that are no complica-
tions with the intracellular folding of collagens. This was conﬁrmed
in a luciferase reporter assay, showing that miR-148a interacts with
MMP13, COL10A1 andADAMTS5, but notwith SERPINH1or COL2A1.
In addition to modulating matrix protein expression by binding
target mRNA or repressormRNA of matrix gene expression, another
mechanism by which hsa-miR-148a may target cartilage meta-
bolism, is by affecting methylation pathways, as miR-148a directly
targets DNA methyltransferase 1 (DNMT1)38e41. Lower expression
of miR-148a could increase DNMT1 expression and attenuate DNA
Fig. 5. Collagen content (A), release (B), and total production (C) (determined as hydroxyproline (normalized for the DNA content)), collagenase activity (D) and type II collagen (E,
determined by immunoblot) were determined after 21 days in cultures of OA chondrocytes transfected with a pre-mir miRNA precursor negative control (mock) or a pre-mir miRNA
precursor for hsa-miR-148a (miR-148a). The data are presented in a dot plot where every dot resembles the value of one donor. The mean value of the samples is indicated by a line.
(E) The ﬁrst lane contains a protein ladder, the following three standards of 0.005, 0.025, and 0.05 mg type II collagen. *: P < 0.01; ***: P < 0.001.
L.A. Vonk et al. / Osteoarthritis and Cartilage 22 (2014) 145e153 151hypomethylation. It was suggested that changes in DNA methyl-
ation also play a role in the gene expression patterns observed in
OA10, and thus hsa-miR-148a might also modulate cartilage matrix
production through a more general DNA methylation-based way.
Besides hsa-miR-148a, several other miRNAs are already found
to be differentially expressed in OA18e21. Hsa-miR-140 is one of the
most studied miRNAs with respect to cartilage and its expression is
signiﬁcantly lower in OA cartilage compared to healthy cartilage22e
24. Also hsa-miR-27 and hsa-miR-146a levels are signiﬁcantly lower
in OA cartilage compared to healthy cartilage and they are found to
regulate the expression of MMP1325e27. The gene expression of
type II collagen (COL2A1) is indirectly regulated by hsa-miR-675
and miR-145 directly targets SOX928,29.
Although the abovementioned miRNAs were functionally
analyzed, the effects of modulating the expression of these miRNAs
on actual cartilage regeneration, in particular at the protein level,
are unknown. The current study is the ﬁrst investigating the effect
of modulating the expression of a speciﬁc miRNA on the productionand degradation of the main components of cartilage, the pro-
teoglycans and collagens.
In the current study, cartilage production was shown to be
enhanced by overexpression of hsa-miR-148a in OA chondrocytes,
which, in addition to providing information on mechanisms in the
pathogenesis and maintenance of OA, may render this miRNA a
target for a potential therapy for OA or to induce cartilage repair.
Several clinical trials are already ongoing for miRNA-based treat-
ment of hepatitis C42, liver cancer43,44, and heart failure45. However,
a drawback for miRNA-based treatment for cartilaginous tissues is
the relative inaccessibility of chondrocytes. Since cartilage is avas-
cular and the chondrocytes are embedded in a dense and charged
extracellular matrix, it may be difﬁcult to transfect chondrocytes in
the native tissue. However, many advances in transfection of carti-
lage in vivo are currently being achieved46e50, increasing the pos-
sibility of application of miRNA in targeting cartilaginous tissues.
In conclusion, overexpression of hsa-miR-148a stimulated the
production of collagens, speciﬁcally type II collagen, and enhanced
L.A. Vonk et al. / Osteoarthritis and Cartilage 22 (2014) 145e153152the retention and deposition of collagen and proteoglycans,
respectively, in cartilage matrix deposited by OA chondrocytes.
Hsa-miR-148a may be a potential target for the treatment of OA, as
it promotes cartilage production and prevents cartilage degrada-
tion and hypertrophy.
Author contributions
Conception and design: LV, LC, DS.
Collection and assembly of data: LV, AK.
Analysis and interpretation of the data: LV, LC.
Provision of study materials: DS.
Drafting of the article and reviewing: LV, AK, WD, DS, LC.
Final approval of submitted version: LV, AK, WD, DS, LC.
Role of funding source
The funding source had no role in study design, collection, analysis
or interpretation of data, inwriting themanuscript or in submitting
the manuscript.
Conﬂict of interest
The authors declare that they have no competing interests.
Acknowledgments
This research forms part of the project #SSM06004 Trans-
lational Regenerative Medicine of the research program SmartMix,
co-funded by the Dutch Ministry of Economic Affairs, Agriculture
and Innovation. L.B. Creemers is funded by the Dutch Arthritis As-
sociation. D.B.F. Saris receives trial support from Sanoﬁ/Genzyme
and consultancy and teaching fees from Tigenix and Smith &
Nephew.
The authors thank Dr G. Krenning for the pSICHECK2 vector.
References
1. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol
2007;213(3):626e34.
2. Aigner T, Fundel K, Saas J, Gebhard PM, Haag J, Weiss T, et al.
Large-scale gene expression proﬁling reveals major pathoge-
netic pathways of cartilage degeneration in osteoarthritis.
Arthritis Rheum 2006;54(11):3533e44.
3. Malemud CJ, Islam N, Haqqi TM. Pathophysiological mecha-
nisms in osteoarthritis lead to novel therapeutic strategies.
Cells Tissues Organs 2003;174(1e2):34e48.
4. Goldring MB. The role of cytokines as inﬂammatory mediators
in osteoarthritis: lessons from animal models. Connect Tissue
Res 1999;40(1):1e11.
5. Reynard LN, Loughlin J. Genetics and epigenetics of osteoar-
thritis. Maturitas 2012;71(3):200e4.
6. Goldring MB, Marcu KB. Epigenomic and microRNA-mediated
regulation in cartilage development, homeostasis, and osteo-
arthritis. Trends Mol Med 2012;18(2):109e18.
7. Imagawaka K, De Andres MC, Hashimoto K, Pitt D, Itoi E,
Goldring MB, et al. The epigenetic effect of glucosamine and a
nuclear factor-kappa B (NF-kB) inhibitor on primary human
chondrocytes-implications for osteoarthritis. Biochem Biophys
Res Commun 2011;405(3):362e7.
8. Alcaraz MJ, Megias J, Garcia-Arnandis I, Clerigues V, Guillen MI.
New molecular targets for the treatment of osteoarthritis.
Biochem Pharmacol 2010;80(1):13e21.
9. da Silva MA, Yamada N, Clarke NM, Roach HI. Cellular and
epigenetic features of a young healthy and a young osteoar-
thritic cartilage compared with aged control and OA cartilage.
J Orthop Res 2009;27(5):593e601.10. Roach HI, Aigner T. DNA methylation in osteoarthritic chon-
drocytes: a new molecular target. Osteoarthritis Cartilage
2007;15(2):128e37.
11. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often
ﬂanked by adenosines, indicates that thousands of human
genes are microRNA targets. Cell 2005;120(1):15e20.
12. Zalts H, Shomron N. The impact of microRNAs on endocri-
nology. Pediatr Endocrinol Rev 2011;8(4):354e62.
13. Ha TY. MicroRNAs in human diseases: from cancer to cardio-
vascular disease. Immune Netw 2011;11(3):135e54.
14. van Kouwenhove M, Kedde M, Agami R. MicroRNA regulation
by RNA-binding proteins and its implications for cancer. Nat
Rev Cancer 2011;11(9):644e56.
15. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet
2011;12(12):861e74.
16. Bian S, Sun T. Functions of Noncoding RNAs in Neural devel-
opment and neurological diseases. Mol Neurobiol 2011;44(3):
359e73.
17. Kobayashi T, Lu J, Cobb BS, Rodda SJ, McMahon AP, Schipani E,
et al. Dicer-dependent pathways regulate chondrocyte prolif-
eration and differentiation. Proc Natl Acad Sci USA
2008;105(6):1949e54.
18. Iliopoulos D, Malizos KN, Oikonomou P, Tsezou A. Integrative
microRNA and proteomic approaches identify novel osteoar-
thritis genes and their collaborative metabolic and inﬂam-
matory networks. PLoS One 2008;3(11):e3740.
19. Jones SW, Watkins G, Le Good N, Roberts S, Murphy CL,
Brockbank SM, et al. The identiﬁcation of differentially
expressed microRNA in osteoarthritic tissue that modulate the
production of TNF-alpha and MMP13. Osteoarthritis Cartilage
2009;17(4):464e72.
20. Swingler TE, Wheeler G, Carmont V, Elliot HR, Barter MJ, Abu-
Elmagd M, et al. The expression and function of microRNAs in
chondrogenesis and osteoarthritis. Arthritis Rheum
2012;64(6):1909e19.
21. Yu C, Chen WP, Wang XH. MicroRNA in osteoarthritis. J Int
Med Res 2011;39(1):1e9.
22. Araldi E, Schipani E. MicroRNA-140 and the silencing of oste-
oarthritis. Genes Dev 2010;24(11):1075e80.
23. Miyaki S, Sato T, Inoue A, Otsuki S, Ito Y, Yokoyama S, et al.
MicroRNA-140 plays dual roles in both cartilage development
and homeostasis. Genes Dev 2010;24(11):1173e85.
24. Miyaki S, Nakasa T, Otsuki S, Grogan SP, Higashiyama R,
Inoue A, et al. MicroRNA-140 is expressed in differentiated
human articular chondrocytes and modulates interleukin-1
responses. Arthritis Rheum 2009;60(9):2723e30.
25. Akhtar N, Rasheed Z, Ramamurthy S, Anbazhagan AN, Voss FR,
Haggi TM. MicroRNA-27b regulates the expression of matrix
metalloproteinase 13 in human osteoarthritic chondrocytes.
Arthritis Rheum 2010;62(5):1361e71.
26. Yamasaki K, Nakasa T, Miyaki S, Ishikawa M, Deie M, Adachi N,
et al. Expression of microRNA-146a in osteoarthritis cartilage.
Arthritis Rheum 2009;60(4):1035e41.
27. Tardif G, Hum D, Pelletier JP, Duval N, Martel-Pelletier J.
Regulation of the IGFBP-5 and MMP-13 genes by the micro-
RNAs miR-140 and miR-27a in human osteoarthritic chon-
drocytes. BMC Muscoskelet Disord 2009;30:148.
28. Dudek KA, Lafont JE, Martinez-Sanchez A, Murphy CL. Type II
collagen expression is regulated by tissue-speciﬁc miR-675 in
human articular chondrocytes. J Biol Chem 2010;285(32):
24381e7.
29. Martinez-Sanchez A, Dudek KA, Murphy CL. Regulation of
human chondrocyte function through direct inhibition of
cartilage master-regulator SOX9 by miRNA-145. J Biol Chem
2012;287(2):916e24.
L.A. Vonk et al. / Osteoarthritis and Cartilage 22 (2014) 145e153 15330. Takahashi K, Kubo T, Goomer RS, Amiel D, Kobayashi K,
Imanishi J, et al. Analysis of heat shock proteins and cytokines
expressed during early stages of osteoarthritis in a mouse
model. Osteoarthritis Cartilage 1997;5(5):321e9.
31. Van Diest PJ. No consent should be needed for using leftover
body material for scientiﬁc purposes. BMJ 2002;325(7365):
648e51.
32. Kandel RA, Boyle J, Gibson G, Cruz T, Speagle M. In vitro for-
mation of mineralized cartilaginous tissue by articular chon-
drocytes. In Vitro Cell Dev Biol Anim 1997;33(3):174e81.
33. Yang KG, Saris DB, Geuze RE, Helm YJ, Rijen MH, Verbout AJ,
et al. Impact of expansion and redifferentiation conditions on
chondrogenic capacity of cultured chondrocytes. Tissue Eng
2006;12(9):2435e47.
34. Vonk LA, Kroeze RJ, Doulabi BZ, Hoogendoorn RJ, Huang C,
Helder MN, et al. Caprine articular, meniscus and interverte-
bral disc cartilage: an integral analysis of collagen network and
chondrocytes. Matrix Biol 2010;29(3):209e18.
35. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and
discrimination of sulphated glycosaminoglycans by use of
dimethylmethylene blue. Biochim Biophys Acta 1986;883(2):
173e7.
36. Creemers LB, Jansen DC, van Veen-Reurings A, van den Bos T,
Everts V. Microassay for the assessment of low levels of hy-
droxyproline. Biotechniques 1997;22(4):656e8.
37. Lavietes BB. Kinetics of matrix synthesis in cartilage cell cul-
tures. Exp Cell Res 1971;68(1):43e8.
38. Pavicic W, Perkiö E, Kaur S, Peltomäki P. Altered methylation
at microRNA-associated CpG islands in hereditary and spo-
radic carcinoma’s: a methylation-speciﬁc multiplex ligation-
dependent probe ampliﬁcation (MS-MLPA)-based approach.
Mol Med 2011;17(7e8):726e35.
39. Braconi C, Huang N, Patel T. MicroRNA-dependent regulation
of DNA methyltransferase-1 and tumor suppressor gene
expression by interleukin-6 in human malignant chol-
angiocytes. Hepatology 2010;51(3):881e90.40. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-
Cespedes M, Blanco D, et al. A microRNA DNA methylation
signature for human cancer metastasis. Proc Natl Acad Sci USA
2008;105(36):13556e61.
41. Pan W, Zhu S, Yuan M, Cui H, Wang L, Luo X, et al. MicroRNA-
21 and microRNA-148a contribute to DNA hypomethylation in
lupus CD4þ T cells by directly and indirectly targeting DNA
methyltransferase 1. J Immunol 2010;184(12):6773e81.
42. Santaris Pharma. News Release, Santaris Pharma Begins Hu-
man Clinical Testing of the World’s First Medicine Targeted at
a Human MicroRNA 28 May 20081e4.
43. Rosetta Genomics. Initiates In Vivo Studies, Drug Clinical Tri-
als, http://www.emaxhealth.com/95/18136.html; 2007.
44. Company Focus: Diagnostics. Rosetta Genomics, http://www.
rosetta-genomics.com; 2009.
45. Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis,
mechanism, function, and recent clinical trials. Biochim Bio-
phys Acta 2010;1803(11):1231e43.
46. Schiffelers RM, Xu J, Storm G, Woodle MC, Scaria PV. Effects of
treatment with small interfering RNA on joint inﬂammation in
mice with collagen-induces arthritis. Arthritis Rheum
2005;52:1314e8.
47. Grossin L, Cournil-Henrionnet C, Mir LM, Liagre B, Dumas D,
Etienne S, et al. Direct gene transfer into rat articular cartilage
by in vivo electroporation. FASEB J 2003;17:829e35.
48. Suzuki T, Nishida K, Kakutani K, Maeno K, Yurube T, Takada T,
et al. Sustained long-term RNA interference in nucleus pul-
posus cells in vivo mediated by unmodiﬁed small interfering
RNA. Eur Spine J 2009;18:263e70.
49. Pi Y, Zhang X, Shi J, Zhu J, Chen W, Zhang C, et al. Targeted
delivery of non-viral vectors to cartilage in vivo using a
chondrocyte-homing peptide identiﬁed by phage display.
Biomaterials 2011;32:6324e32.
50. Rothenﬂuh DA, Bermudez H, O’Neil CP, Hubbell JA. Bio-
functional polymer nanoparticles for intra-articular targeting
and retention in cartilage. Nat Mater 2008;7:248e54.
